Krystal Biotech, Inc. [●] Shares Common Stock ($0.00001 par value) Underwriting AgreementKrystal Biotech, Inc. • September 14th, 2017 • Biological products, (no disgnostic substances) • New York
Krystal Biotech, Inc., a corporation organized under the laws of Delaware (the “Issuer”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Ladenburg Thalmann & Co. Inc. is acting as representative (the “Representative”), [●] shares of common stock, $0.00001 par value per share (“Common Stock”) of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [●] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representative as used herein shall mean you, as Underwriter, and the terms Representative and Underwriter shall mean either the singular or
FORM OF INDEMNIFICATION AGREEMENT (DIRECTORS)Indemnification Agreement • September 14th, 2017 • Krystal Biotech, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (Directors) (this “Agreement”) is made and entered into on [ ], by and between Krystal Biotech, Inc., a Delaware corporation with a principal business address of 2100 Wharton Street, Suite 701, Pittsburg, PA 15203 (the “Company”), and [ ], an individual resident of the State of [ ] with a residential address as set forth on the signature page hereto (“Indemnitee”), to be effective as of [ ], 20[ ] (the “Effective Date”).
